GMP Monoclonal Anti-Human CD16 Antibody (3G8)

Premium grade (Pre-GMP) version CD6-CH29G1 is now available for seamless transition.
1/5
+2 View all
製品番号/仕様
価格
Availability
数量
GMP-MC1639-500ug
$1,500.00
In Stock - Delivery in 2-3 business days
GMP-MC1639-2.5mg (500ug X 5)
$5,000.00
GMP-MC1639
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Product Features and Advantages
  • Wide-ranging functions: Acts as a key functional reagent to support the specific activation and expansion of natural killer (NK) cells in adoptive cell therapy workflows, while enhancing antibody-dependent cellular cytotoxicity (ADCC) and effector function in CAR-NK, TIL, and NK cell cultures.
  • High Performance: Exhibits superior binding specificity to CD16 and potent biological activity, making it the preferred choice for numerous pharmaceutical enterprises in preclinical and clinical-stage NK cell therapy development and cancer immunotherapy research.
  • Comprehensive Safety Assurance: ATCC-compliant CHO host cell origin and comprehensive testing (52 items), animal origin-free (AOF) production process, with stringent final product quality control and release specifications to support clinical-grade applications.
  • Lot-to-Lot Consistency: Achieved through a stable cell line and robust manufacturing process, ensuring reliable, reproducible functional performance from early-stage research through clinical manufacturing.
GMP Platform Advantages
  • Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
  • End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
  • Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
  • Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
  • Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
  • Professional Support: Extensive manufacturing and application expertise to accelerate development.
Source

GMP Monoclonal Anti-Human CD16 Antibody (3G8) (GMP-MC1639) is recombinantly produced from CHO cells.

Isotype

Mouse IgG1, Kappa

Specificity

This product is a specific antibody that specifically reacts with CD16/Fc gamma RIII.

Endotoxin

Less than 2 EU/mg, tested by the rFC method in compliance with USP <86> and Ph. Eur. 2.6.32.

Protein A

<5 ppm of protein tested by ELISA.

Host Cell Protein

<0.5 ng/μg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by qPCR.

Purity

>95% as determined by SDS-PAGE.

Sterility

Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

Mycoplasma

Negative

Formulation

Supplied as 0.2 μm filtered solution in PBS, pH7.4 with protectants.

Contact us for customized product form or formulation.

Vial Specification

2R (13 mm neck finish)

Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

Storage

For long term storage, the product should be stored at liquid state at -70°C.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -70°C for 5 years;
  • -20°C for 12 months under sterile conditions;
  • 2-8°C for 6 months under sterile conditions.

バックグランド

CD16 encodes a receptor that recognizes the Fc portion of immunoglobulin G and is involved in the clearance of immune complexes from the circulation, as well as other functions such as cellular mediated cytotoxicity and enhancement of virus infections. This gene, FCGR3A, shares a high degree of similarity with another nearby gene, FCGR3B, located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, while FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been associated with immunodeficiency 20 and have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. Diseases associated with FCGR3A include Immunodeficiency 20 and Herpes Zoster.